ReviewJournal of cardiac failure2022
Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review.
Review in Journal of cardiac failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 81 citations in OpenAlex.
- The double threat: imaging manifestations of thoracic sarcoidosis with miliary nodules and myocardial involvement with radiologic-pathologic correlation.The international journal of cardiovascular imaging · 2026Article
- Cardiac sarcoidosis: new insights beyond the granuloma using spatial proteomics.European heart journal · 2026Article
- Cardiac sarcoidosis presenting as sustained ventricular tachycardia mimicking arrhythmogenic right ventricular cardiomyopathy.HeartRhythm case reports · 2026Article
- Electrocardiographic abnormalities attributable to infiltrative cardiomyopathies: review and prevalence in patients with congestive heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Review
- Clinical and imaging profiling of restrictive cardiomyopathies: insights into amyloid, sarcoid, and iron overload phenotypes.Heart failure reviews · 2026Review
- The Role of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Sarcoid Cardiomyopathy: A Multicenter Retrospective Cohort Study.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Article
- Article
- Management of Clinical Cardiac Sarcoidosis Isolated to the Heart With Tumor Necrosis Factor-Alpha Inhibitors.JACC. Case reports · 2025Article
- Sex differences in cardiac sarcoidosis.International journal of cardiology. Heart & vasculature · 2025Article
- Diagnoses and outcomes of patients referred for FDG PET/CT for suspected cardiac sarcoidosis.International journal of cardiology · 2025Article
- Article
- The Evolving Field of Cardio-Rheumatology: Global Patterns and Research Gaps, 1953-2025.Cureus · 2025Review
- Delays in Referral to Multidisciplinary Care for Black Individuals With Sarcoidosis.CHEST pulmonary · 2025Article
- Cardiac Magnetic Resonance Imaging in the Evaluation and Prognosis of Infiltrative Cardiomyopathies.Journal of cardiovascular development and disease · 2025Review
- Diagnostic Value of Comprehensive Echocardiographic Assessment Including Speckle-Tracking in Patients with Sarcoidosis Versus Healthy Controls: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Review
- Review
- Cardiac Sarcoidosis: Clinical Insights, Diagnosis, and Management Strategies.Reviews in cardiovascular medicine · 2025Review
- Understanding the prevalence, in-hospital mortality and readmission rates amongst pulmonary vs cardiac sarcoidosis patients: insights from a nationwide registry.American journal of cardiovascular disease · 2025Article
- Clinical outcomes of isolated versus systemic cardiac sarcoidosis: a systematic review and meta-analysis.Archives of medical sciences. Atherosclerotic diseases · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 2 countries.
Funding
Abstract
The prevalence of sarcoidosis-related cardiomyopathy is increasing. Sarcoidosis impacts cardiac function through granulomatous infiltration of the heart, resulting in conduction disease, arrhythmia, and/or heart failure. The diagnosis of cardiac sarcoidosis (CS) can be challenging and requires clinician awareness as well as differentiation from overlapping diagnostic phenotypes, such as other forms of myocarditis and arrhythmogenic cardiomyopathy. Clinical manifestations, extracardiac involvement, histopathology, and advanced cardiac imaging can all lend support to a diagnosis of CS. The mainstay of therapy for CS is immunosuppression; however, no prospective clinical trials exist to guide management. Patients may progress to developing advanced heart failure or ventricular arrhythmia, for which ventricular assist device therapies or heart transplantation may be considered. The existing knowledge gaps in CS call for an interdisciplinary approach to both patient care and future investigation to improve mechanistic understanding and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.